Cell-free DNA and RNA in plasma as a new molecular marker for prostate cancer

被引：43

作者：

Papadopoulou, E

Davilas, E

Sotiriou, V

Koliopanos, A

Aggelakis, F

Dardoufas, K

Agnanti, NJ

Karydas, L

Nasioulas, G

机构：

[1] HYGEIA Antonios Papayannis, Mol Biol Res Ctr, Athens 15123, Hellas, Greece

[2] HYGEIA, Duagnost & Therapeut Ctr Athens, Urol Clin, Athens 15123, Hellas, Greece

[3] Gen State Hosp Athens G Gennimatas, Surg Clin, Athens, Hellas, Greece

[4] HYGEIA, Ctr Radiat Oncol, Diagnost & Therapeut Ctr Athens, Athens 15123, Hellas, Greece

[5] Univ Ioannina, Sch Med, Dept Pathol, Hellas, Greece

[6] HYGEIA, Breast Ctr, Diagnost & Therapeut Ctr Athens, Athens 15123, Greece

来源：

ONCOLOGY RESEARCH | 2004年 / 14卷 / 09期

关键词：

prostate-specific membrane antigen (PSMA); glutathione-S-transferase P1 (GSTP1); carcinoembryonic antigen (CEA); DNA quantification;

D O I：

10.3727/0965040041791473

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Extracellular nucleic acids could serve as molecular markers in the early detection of cancer and in the prediction of disease outcome. In this study we examined six molecular markers, such as: variations in the quantity of DNA in plasma, glutathione-S-transferase P1 (GSTP1) gene methylation status in plasma, carcinoembryonic antigen (CEA) and prostate-specific membrane antigen (PSMA) mRNA in peripheral blood mononuclear cells (PBMC), and plasma samples from prostate cancer patients in different stages. The combination of DNA load and GSTP1 promoter methylation status identified 83% (10/12) of the prostate cancer patients before therapy. This study shows that free circulating DNA can be detected in patients with prostate cancer compared with disease-free individuals, and suggests a new, noninvasive approach for early detection of prostate cancer.

引用

页码：439 / 445

页数：7